Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M9140 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
M9140 + bevacizumab is an investigational **combination therapy** for advanced solid tumors, specifically evaluated in metastatic colorectal cancer. **M9140** (precemtabart tocentecan) is an antibody-drug conjugate (ADC) that targets CEACAM5, a protein frequently overexpressed in colorectal and other epithelial cancers. The ADC consists of a humanized anti-CEACAM5 antibody linked to the topoisomerase I inhibitor exatecan (payload), enabling targeted cytotoxicity to CEACAM5-expressing tumor cells. **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), suppressing tumor angiogenesis. This combination is designed to deliver a targeted anti-tumor cytotoxic effect (via M9140) while simultaneously blocking tumor angiogenesis (via bevacizumab), potentially improving efficacy in refractory metastatic colorectal cancer[1][2][3][5]. Primary indications under investigation include metastatic colorectal cancer in patients who are refractory or intolerant to established therapies.
- Other names
- M9140 + bevacizumab
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on M9140 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M9140 + bevacizumab.